Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) Testing Market Report 2026

The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.43 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing screening of sexually active populations, expansion of laboratory-based testing infrastructure, adoption of NAAT and PCR technologies, rising awareness of co-infection risks, growth of diagnostic laboratories.

The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size is expected to see strong growth in the next few years. It will grow to $3.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing investments in decentralized testing, rising adoption of home-based diagnostics, expansion of automated laboratory platforms, growing focus on early STI detection, increasing demand for integrated CT/NG testing solutions. Major trends in the forecast period include increasing adoption of multiplex sti testing panels, rising demand for rapid point-of-care testing, growing use of self-testing kits, expansion of high-sensitivity molecular assays, enhanced integration of laboratory automation.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the coming years. STIs are infections caused by bacteria, viruses, or parasites that can be transmitted through sexual contact. Factors contributing to increasing STI rates include limited comprehensive sex education, higher sexual activity, social stigma, and barriers to testing and care. CT and NG testing plays a critical role in managing STIs by enabling early diagnosis, timely treatment, and prevention of transmission. For example, in October 2025, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that approximately 39.9 million individuals worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children. Consequently, the growing prevalence of STIs is fueling the demand for CT and NG testing.

Key companies in the CT and NG testing market are focusing on innovations such as rapid molecular point-of-care diagnostics to enable faster, more accurate onsite detection and improve timely treatment outcomes. Point-of-care molecular diagnostics allow immediate detection of infections like chlamydia without relying on centralized laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, received FDA 510(k) clearance and a CLIA waiver for its cobas® liat molecular tests. These tests are designed to diagnose STIs at the point of care using multiplex assay panels capable of detecting and differentiating multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, with results available in 20 minutes or less.

In December 2023, Imaware, a US-based health testing company, acquired the consumer testing business from Binx Health for an undisclosed amount. This acquisition enables Imaware to expand its portfolio in consumer diagnostics, broadening access to STI screening and other health tests. Binx Health is a US-based company specializing in at-home and point-of-care diagnostic testing solutions, particularly in sexual health.

Major companies operating in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc, PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc, Meridian Bioscience Inc, Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd, Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd, NG Biotech.

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2025. The regions covered in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the CT and NG testing market by increasing costs of imported molecular reagents, assay kits, analyzers, and imaging components used in laboratory and point-of-care testing systems. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-precision testing equipment, while Asia-Pacific faces higher manufacturing costs for exported kits. These tariffs are elevating test pricing and influencing procurement cycles. However, they are also promoting regional manufacturing of test kits, localized analyzer assembly, and innovation in cost-efficient diagnostic technologies.

The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market research report is one of a series of new reports that provides chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market statistics, including chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market share, detailed chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing industry. This chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing refers to procedures for diagnosing sexually transmitted infections (STIs) caused by Chlamydia trachomatis and Neisseria gonorrhoeae in sexually active individuals, particularly those with multiple partners or who engage in unprotected sexual activity. These tests are performed to detect the presence of these bacteria, typically using urine samples, genital swabs, or blood tests.

The main types of CT and NG testing include laboratory testing and point-of-care testing. Laboratory testing is conducted in facilities equipped with specialized instruments and trained personnel to analyze patient samples for CT and NG infections. These tests use a variety of products, including assays, kits, and analyzers, and leverage technologies such as isothermal nucleic acid amplification, polymerase chain reaction (PCR), immunodiagnostics, and others. The primary end users for these tests include diagnostic laboratories, hospitals, clinics, and other healthcare settings.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.